Different responses of cell cycle between rat vascular smooth muscle cells and vascular endothelial cells to paclitaxel

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 34, Issue 3, 2014, Pages 370-375

  Jing, Liang ^a   Peng, Xi ^a   Xie, Min Jie ^a   Yu, Zhi Yuan ^a   Wang, Wei ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

drug eluting stent; paclitaxel; vascular endothelial cells; vascular smooth muscle cells

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; PACLITAXEL; TUBULIN MODULATOR;

ANIMAL; ARTICLE; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECT; ENDOTHELIUM CELL; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; G1 PHASE CELL CYCLE CHECKPOINT; IMMUNOHISTOCHEMISTRY; METABOLISM; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN B1; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ENDOTHELIAL CELLS; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINTS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, FLUORESCENCE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PACLITAXEL; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; TUBULIN MODULATORS;

EID: 84903986276     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-014-1285-1     Document Type: Article

References (29)

1. Loh JP, Waksman R. Paclitaxel drug-coated balloons: a review of current status and emerging applications in native coronary artery de novo lesions. JACC Cardiovasc Interv, 2012, 5(10):1001-1012
2. Ko YG, Kim JS, Kim BK, et al. Efficacy of drug-eluting stents for treating in-stent restenosis of drug-eluting stents (from the Korean DES ISR multicenter registry study [KISS]). Am J Cardiol, 2012, 109(5):607-613
3. Kibos A, Campeanu A, Tintoiu I, et al. Pathophysiology of coronary artery in-stent restenosis. Acute Card Care, 2007, 9(2):111-119
4. Qiu J, Gao HQ, Li BY, et al. Proteomics investigation of protein expression changes in ouabain induced apoptosis in human umbilical vein endothelial cells. J Cell Biochem, 2008, 104(3):1054-1064
5. Inoue T, Node K. Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J, 2009, 73(4):615-621
6. Ribamar Costa J, Sousa AG, Moreira A, et al. Comparison of the very long term (>1 year) outcomes of drug-eluting stents for the treatment of bare-metal and drug-eluting stent restenosis. Euro Intervention, 2009, 5(4):448-453
7. Lee SE, John SH, Lim JH, et al. Very late stent thrombosis associated with multiple stent fractures and peri-stent aneurysm formation after sirolimus-eluting stent implantation. Circ J, 2008, 72(7):1201-1204
8. Luk SC, Siu SW, Lai CK, et al. Cell cycle arrest by a natural product via G2/M checkpoint. Int J Med Sci, 2005, 5(5):64-69
9. Boye E, Skjolberg HC, Grallert B. Checkpoint regulation of DNA replication. Methods Mol Biol, 2009, 521:55-70
10. Collins I, Garrett MD. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol, 2005, 5(4):366-373
11. Kobayashi M, Inoue K, Warabi E, et al. A simple method of isolating mouse aortic endothelial cells. J Atheroscler Thromb, 2005, 12(3):138-142
12. Wang DG, Liu ZY, Bi YS, et al. Culture of smooth muscle cells from guinea pig mesenteric lymphatic vessels. Lymphology, 2007, 40(1):14-18
13. Munari LM, Porta M. Cerebrovascular disease: pathophysiology and clinical aspects. Rays, 1990, 15(2): 153-164
14. Breen DM, Chan KK, Dhaliwall JK, et al. Insulin increases reendothelialization and inhibits cell migration and neointimal growth after arterial injury. Arterioscler Thromb Vasc Biol, 2009, 29(7):1060-1066
15. Sun ZS, Zhou SH, Guan X. Impact of blood circulation on reendothelialization, restenosis and atrovastatin's restenosis prevention effects. Int J Cardiol, 2008, 128(2): 261-8
16. El-Kareh AW, Labes RE, Secomb TW. Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs. AAPS J, 2008, 10(1):15-34
17. Sroka IM, Heiss EH, Havlicek L, et al. A novel roscovitine derivative potently induces G1-phase arrest in platelet-derived growth factor-BB-activated vascular smooth muscle cells. Mol Pharmacol, 2010, 77(2): 255-261
18. Thipparaboina R, Khan W, Domb AJ. Eluting combination drugs from stents. Int J Pharm, 2013, pii: S0378-5173(13)00609-1
19. Masaki T, Kamerath CD, Kim SJ, et al. In vitro pharmacological inhibition of human vascular smooth muscle cell proliferation for the prevention of hemodialysis vascular access stenosis. Blood Purif, 2004, 22(3):307-312
20. Xiao Z, Xue J, Sowin TJ, et al. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol Cancer Ther, 2006, 5(8): 1935-1943
21. Klopfleisch R, Gruber AD. Differential expression of cell cycle regulators p21, p27 and p53 in metastasizing canine mammary adenocarcinomas versus normal mammary glands. Res Vet Sci, 2009, 87(1):91-6
22. Hirai H, Roussel MF, Kato JY, et al. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol, 1995, 15(5):2672-2681
23. Butler JE, Spear BT. Normal intestinal epithelial cell differentiation in the absence of p21 and p27: new insights from old knock-out mice. Cancer Biol Ther, 2008, 7(6):880-881
24. Fasciano S, Patel RC, Handy I, et al. Regulation of vascular smooth muscle proliferation by heparin: inhibition of cyclin-dependent kinase 2 activity by p27(kip1). J Biol Chem, 2005, 280(16):15682-15689
25. Masamha CP, Benbrook DM. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res, 2009, 69(16):6565-6572
26. Elmore LW, Di X, Dumur C, et al. Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response. Clin Cancer Res, 2005, 11(7):2637-2643
27. Zhao YM, Zhou Q, Xu Y, et al. Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition. Acta Pharmacol Sin, 2008, 29(4):481-488
28. Tiroch K, Koch W, Mehilli J, et al. P27 and P53 gene polymorphisms and restenosis following coronary implantation of drug-eluting stents. Cardiology, 2009, 112(4): 263-269
29. Fuchs AT, Kuehnl A, Pelisek J, et al. Inhibition of restenosis formation without compromising reendothelialization as a potential solution to thrombosis following angioplasty? Endothelium, 2008, 15(1):85-92